Radioimmunotherapy (RIT) series for transformed lymphomas (TL).
| Study . | Agent . | N . | Response rate, % . | Median duration of response, mo. (95% CI) . | CR/Cru, % . | Median duration of response for CR/CRu, mo (95% CI) . |
|---|---|---|---|---|---|---|
| I131 indicates iodine I131 tositumomab (Bexxar); Y90, yttrium Y90 ibritumomab tiuxetan (Zevalin); mo., months; 95% CI, 95% confidence interval; NR, not reached; CR, complete response; Cru, complete response unconfirmed; N/A, data not available | ||||||
| *compilation of data from 5 iodine I131 tositumomab (Bexxar) studies | ||||||
| Kaminsky 53 | I131 | 14 | 79 | 13.9 | 50 | – |
| Vose 51 | I131 | 10 | 60 | 12.1 (4.5-NR) | 50 | 14.3 |
| Davies 52 | I131 | 7 | 71 | 41.0 (4-NR) | 29 | NR |
| Witzig 54 | Y90 | 9 | 56 | N/A | N/A | N/A |
| Zelenetz 55* | I131 | 71 | 39 | 14.7 (10.8–40.8) | 25 | 36.5 (14.4–59.1) |
| Study . | Agent . | N . | Response rate, % . | Median duration of response, mo. (95% CI) . | CR/Cru, % . | Median duration of response for CR/CRu, mo (95% CI) . |
|---|---|---|---|---|---|---|
| I131 indicates iodine I131 tositumomab (Bexxar); Y90, yttrium Y90 ibritumomab tiuxetan (Zevalin); mo., months; 95% CI, 95% confidence interval; NR, not reached; CR, complete response; Cru, complete response unconfirmed; N/A, data not available | ||||||
| *compilation of data from 5 iodine I131 tositumomab (Bexxar) studies | ||||||
| Kaminsky 53 | I131 | 14 | 79 | 13.9 | 50 | – |
| Vose 51 | I131 | 10 | 60 | 12.1 (4.5-NR) | 50 | 14.3 |
| Davies 52 | I131 | 7 | 71 | 41.0 (4-NR) | 29 | NR |
| Witzig 54 | Y90 | 9 | 56 | N/A | N/A | N/A |
| Zelenetz 55* | I131 | 71 | 39 | 14.7 (10.8–40.8) | 25 | 36.5 (14.4–59.1) |